98%
921
2 minutes
20
Breast cancer remains a significant global health challenge, necessitating innovative therapeutic strategies. This study introduces a novel Q-MX-ZMOF@CH nanocomposite, integrating MXene with zinc-based metal-organic frameworks (ZMOF) and chitosan (CH) to targeted quercetin (Q) delivery and enhanced photothermal therapy (PTT) for breast cancer therapy. TEM imaging of Q-MX-ZMOF@CH indicated spherical morphologies with size distribution (∼60 nm). Q-MX-ZMOF@CH exhibited robust physical, chemical, and functional stability, with sustained Q release under near-infrared (NIR) achieving >98 % release. Q-MX-ZMOF@CH demonstrated high encapsulation efficiency (89.23 %), with high PT conversion efficiency (75.1 %) under NIR. In-vitro studies on MCF-7 breast cancer cells showed significant cytotoxicity (IC = 19.4 μg/mL) and pronounced apoptotic induction. Western blot analysis revealed substantial downregulation of heat shock proteins (HSP70, HSP90, HSP27), suggesting a mechanism for overcoming cellular thermoresistance. In-vivo xenograft studies in BALB/c mice confirmed enhanced bioavailability and improved pharmacokinetic parameters, demonstrating the nanoplatform's potential as a sophisticated, targeted approach to breast cancer treatment. The survival analysis further showed extended survival in tumor-bearing mice treated by Q-MX-ZMOF@CH relative to Q and control groups. Serum biochemistry demonstrated that Q elevated hepatic (ALT, AST, ALP) and renal (creatinine, BUN) markers, indicative of hepatic and renal stress, whereas nanocarrier encapsulation significantly attenuated these alterations. Q-MX-ZMOF@CH reduced inflammatory cytokines (IL-1β, IL-6, TNF-α) and lipid peroxidation (MDA), and enhanced antioxidant enzyme activity (SOD, GPx). Overall, these results establish MX-ZMOF@CH as a biocompatible and efficient drug delivery (DD) platform that enhances the treatment efficacy and safety profile of Q, supporting its potential translation into biomedical applications for tumor and inflammatory disease therapy.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijbiomac.2025.147294 | DOI Listing |
JAMA Netw Open
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.
Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.
Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.
Obstet Gynecol
July 2025
Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.
Med Oncol
September 2025
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Neuropeptide Y (NPY) and the voltage-gated potassium channel Kv1.3 are closely associated with breast cancer progression and apoptosis regulation, respectively. NPY receptors (NPYRs), which are overexpressed in breast tumors, contribute to tumor growth, migration, and angiogenesis.
View Article and Find Full Text PDFIn Vitro Cell Dev Biol Anim
September 2025
Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-shi, Okayama, 700-8558, Japan.
S100 protein family members S100A8 and S100A9 function primarily as a heterodimer complex (S100A8/A9) in vivo. This complex has been implicated in various cancers, including gastric cancer (GC). Recent studies suggest that these proteins play significant roles in tumor progression, inflammation, and metastasis.
View Article and Find Full Text PDFJ Neurooncol
September 2025
Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Purpose: Breast cancer (BC) is the most frequent cancer among women and the second leading cause of central nervous system (CNS) metastases. While the epidemiology of CNS metastases from BC has been well described, little is known about the treatment patterns and outcomes of young women < 40 years of age with BC that is metastatic to the CNS.
Methods: In this retrospective analysis, we identified patients with metastatic breast cancer (MBC) to the CNS who were treated at the Sunnybrook Odette Cancer Center, Toronto, Canada between 2008 and 2018.